HCW Biologics (HCWB) EBT (2020 - 2026)

HCW Biologics (HCWB) has reported EBT for 7 consecutive years, with -$5.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 170.74% year-over-year to -$5.2 million; the trailing twelve-month figure through Jun 2026 stood at -$15.2 million (down 32.86% YoY), and the FY2025 full-year result was -$14.0 million, up 53.48% from the prior year.
• EBT fell to -$5.2 million in Q2 2026 per HCWB's latest filing, from -$4.7 million in the prior quarter.
• Across five years, EBT topped out at -$1.9 million in Q1 2022 and bottomed at -$15.3 million in Q2 2024.
• Historically, EBT has averaged -$5.2 million across 5 years, with a median of -$4.6 million in 2023.
• The sharpest annual moves came in 2024 and 2025: EBT plunged 232.08% in 2024, then soared 87.4% in 2025.
• Over 5 years, EBT stood at -$5.8 million in 2022, then tumbled by 86.87% to -$10.8 million in 2023, then soared by 68.35% to -$3.4 million in 2024, then plunged by 37.15% to -$4.7 million in 2025, then retreated by 11.67% to -$5.2 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$5.2 million, -$4.7 million, and -$3.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.